5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Molecular results and potential biomarkers identified from the phase 3 MILO/ENGOT-ov11 study of binimetinib versus physician choice of chemotherapy in recurrent low-grade serous ovarian cancer
    Journal Article

    Grisham, R. N.; Vergote, I.; Banerjee, S.; Drill, E.; Kalbacher, E.; Mirza, M. R.; Romero, I.; Vuylsteke, P.; Coleman, R. L.; Hilpert, F.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Genomic portraits: Reflections into a tumor’s response to therapy
    Editorial

    Slovin, S. F.
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: Diagnostic performance and outcomes using biparametric vs. multiparametric MRI
    Journal Article

    Woo, S.; Becker, A. S.; Das, J. P.; Ghafoor, S.; Arita, Y.; Benfante, N.; Gangai, N.; Teo, M. Y.; Goh, A. C.; Vargas, H. A.
    Cancer Imaging (2023)

    Fulltext@MSK | Save
  • Multimodal imaging of metabolic activities for distinguishing subtypes of breast cancer
    Journal Article

    Li, Z.; Nguyen, C.; Jang, H.; Hoang, D.; Min, S.; Ackerstaff, E.; Koutcher, J. A.; Shi, L.
    Biomedical Optics Express (2023)

    Fulltext@MSK | Save
  • Impact of tumor metabolism on the microenvironment and response to immunotherapy
    Meeting Abstract

    Zappasodi, R.; Serganova, I.; Brunschvig, S.; Santhella, A.; Mane, M.; Vemuri, K.; Ijoma, J.; Kang, W.; Manovatodorova, K.; Koutcher, J.; more...
    Cancer Science (2023)

    Fulltext@MSK | Save
  • Clonal hematopoiesis and risk of lethal prostate cancer: a prospective cohort study with long-term follow-up
    Meeting Abstract

    Stopsack, K. H.; Chan, I. C.; Schmidt, E.; Panchot, A.; McNulty, S.; Schreiber, N. A.; Zhang, Y. W.; Penney, K. L.; Berger, M. F.; Diaz, L. A.; more...
    Cancer Prevention Research (2023)

    Fulltext@MSK | Save
  • Final database lock results of the phase 2 cohort of lenvatinib + pembrolizumab for progressive disease after a PD-1/PD-L1-containing therapy in metastatic clear cell renal cell carcinoma
    Meeting Abstract

    Lee, C. H.; Shah, A. Y.; Rao, A.; Taylor, M. H.; Pinto, A.; Sarrio, R. G.; Cohn, A. L.; Bilen, M. A.; Ribe, S. G.; Goksel, M.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Zanzalintinib in combination with immune checkpoint inhibitors: Design of the renal cell carcinoma expansion stage cohorts in STELLAR-002
    Meeting Abstract

    Motzer, R. J.; Choueiri, T. K.; Garmezy, B.; O'Neil, B.; Michalski, J.; Barata, P.; Bajaj, A.; Chahoud, J.; Liu, M.; Xu, F.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Functional and translational consequences of immunometabolic coevolution in ccRCC
    Meeting Abstract

    Reznik, E.; Tang, C.; Xie, A.; Liu, E. M.; Kuo, F.; Kim, M.; Golkaram, M.; Chen, Y.; Gupta, S.; Motzer, R.; more...
    The Oncologist (2023)

    Fulltext@MSK | Save
  • Immunotherapy in the treatment of localized genitourinary cancers
    Review

    Necchi, A.; Faltas, B. M.; Slovin, S. F.; Meeks, J. J.; Pal, S. K.; Schwartz, L. H.; Huang, R. S. P.; Li, R.; Manley, B.; Chahoud, J.; more...
    JAMA Oncology (2023)

    Fulltext@MSK | Save